Literature DB >> 28264867

A New Approach to PCSK9 Therapeutics.

Nan Wang1, Alan R Tall2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28264867      PMCID： PMC5848492          DOI： 10.1161/CIRCRESAHA.117.310610

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  14 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.

Authors:  Abdur Rahman Khan; Chirag Bavishi; Haris Riaz; Talha A Farid; Sobia Khan; Michel Atlas; Glenn Hirsch; Sohail Ikram; Roberto Bolli
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-01

3.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

4.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

5.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

6.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

7.  Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Authors:  Ahmed Zaid; Anna Roubtsova; Rachid Essalmani; Jadwiga Marcinkiewicz; Ann Chamberland; Josée Hamelin; Michel Tremblay; Hélène Jacques; Weijun Jin; Jean Davignon; Nabil G Seidah; Annik Prat
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

8.  Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

Authors:  Eli M Roth; James M McKenney; Corinne Hanotin; Gaelle Asset; Evan A Stein
Journal:  N Engl J Med       Date:  2012-10-31       Impact factor: 91.245

9.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Authors:  Kevin Fitzgerald; Suellen White; Anna Borodovsky; Brian R Bettencourt; Andrew Strahs; Valerie Clausen; Peter Wijngaard; Jay D Horton; Jorg Taubel; Ashley Brooks; Chamikara Fernando; Robert S Kauffman; David Kallend; Akshay Vaishnaw; Amy Simon
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

10.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Authors:  Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245
View more
  2 in total

1.  Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.

Authors:  Pragyi Shrestha; Saritha Adepu; Romain R Vivès; Rana El Masri; Astrid Klooster; Fleur Kaptein; Wendy Dam; Stephan J L Bakker; Harry van Goor; Bart van de Sluis; Jacob van den Born
Journal:  J Am Soc Nephrol       Date:  2021-03-23       Impact factor: 14.978

Review 2.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.